Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Is Eli Lilly a good stock to buy on the dip ... Last July, Lilly's Alzheimer's disease candidate Kisunla earned approval from the FDA to treat Alzheimer's disease. Intended for early-stage patients ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to acquire ...